Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Stock Information for Orchestra BioMed Holdings Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Orchestra BioMed Holdings Inc Com

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Orchestra BioMed to Host Business Update Call on November 12, 2025
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.